Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trials Not Allowed)
Attention Biorepositories and Biospecimen Science Programs! The earliest submission date for this National Cancer Institute Funding Opportunity Announcement (FOA) is December 11, 2021.
This NCI FOA will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies and blood biospecimens utilized as “liquid biopsies.” Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), pleural aspirates, and blood utilized for liquid biopsies. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.
Next Application Due Date: January 11th, 2022
Find the full announcement here: https://grants.nih.gov/grants/guide/pa-files/PAR-22-049.html